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Several putative markers of inflammation have been studied
in the gaseous phase and in condensate of exhaled air, mainly
in adults. Among these markers are nitric oxide (NO), carbon
monoxide (CO), and, in breath condensate, hydrogen perox-
ide (H
 
2
 
O
 
2
 
) and leukotrienes (LTs). The methodology for
these measurements has not been standardized, although sev-
eral guidelines for the measurement of NO have been and will
be published. A rapidly growing body of literature supports
the use of NO as an inflammatory marker in asthma, where it
may be useful for diagnosis and perhaps monitoring of (com-
pliance with) treatment. Equipment to measure exhaled NO
(eNO) for medical purposes has become commercially avail-
able. Although this equipment is still expensive and clumsy,
there seems to be increasing interest to buy NO analyzers for
clinical purposes. However, even for NO, there is little if any
literature supporting its value in clinical practice, especially in
pediatric patients. This overview focuses on NO and other
possible markers of inflammation in exhaled air and air con-
densate, briefly summarizes some of the published data, and
indicates gaps in knowledge with respect to pediatrics.
 
WHAT DO WE KNOW?
 
Inflammation Markers in Exhaled Air
 
Nitric oxide:
 
 
 
Measurement of NO.
 
 NO can be measured by
means of chemiluminescence, a method that has long been
used in monitoring air pollution. The equipment is robust, and
measures NO by bringing it into contact with ozone, which
leads to the formation of an unstable reaction product that dis-
integrates and produces a single photon. The photon is de-
tected by a photomultiplier tube and the number of photons is
equal to the number of NO molecules entering the analyzer.
NO analyzers for medical use are fast and allow evaluation of
changes in eNO within breaths. They usually display the NO
value while taking the measurements. Calibration takes place
with certified NO gases and NO-free gas, and there is a linear
relation between NO concentration and output of the ana-
lyzer. Various conditions may affect NO measurements. The
presence of water vapor may lower NO readings (1) and
therefore it is recommended that an (NO-inert) water ab-
sorber be used in the collection system. Also, inhalation of
 
L
 
-arginine, the substrate of NO synthase, has some effect on
eNO (2), but this seems to be of little practical importance. Al-
cohol traces may give a false positive NO reading (3), and
therefore it is recommended that materials used for measure-
ment of NO not be cleaned with alcohol.
 
Sampling of exhaled air for NO measurements.
 
 Extensive
recommendations were published by a European Respiratory
Society task force (4), and even more detailed guidelines were
produced during an American Thoracic Society workshop in
1998 (5). Despite these publications, several aspects of ex-
haled NO sampling remain to be explored, and there are in-
sufficient data from which to produce guidelines for all aspects
of the measurements. Among these are measurements in
young children and off-line techniques (6). To date, NO has
been studied extensively in adults and school-age children but
only a few studies involving preschool children and infants
have been published.
NO diffuses from the walls of the airways, enriching the es-
sentially NO-free alveolar air traveling to the mouth during
expiration. Hence, eNO concentrations are flow dependent,
and one way to standardize for this is to sample during slow
exhalation at a constant flow. The added value of measuring
exhaled CO
 
2
 
 has not been demonstrated; some analyzers have
built-in capnographs and recommend that NO is measured at
the alveolar plateau of CO
 
2
 
. However, as NO has no “alveolar
plateau” and eNO is determined by factors entirely different
from exhaled CO
 
2
 
, the combination of the two measurements
seems to make little sense (7).
Breath holding leads to accumulation of NO in the airways
and should be avoided. NO is not only generated in the lower
airways, but also in the nose (8), paranasal sinuses (9), and in
the oropharynx (10). Contamination of eNO with much higher
NO concentrations from the nose or stomach should be
avoided, and this is generally achieved by applying a fixed pos-
itive mouth pressure during exhalation to close the soft palate.
Grossly, two sampling methods can be distinguished: on-line
and off-line sampling.
 
On-line sampling.
 
 With on-line sampling, gas is sampled by
the analyzer at a fixed flow from a side port in an exhalation
circuit. The subject is seated next to the analyzer and produces
a constant flow against a fixed resistance to elevate oral pres-
sure. Flow and pressure are regulated by means of a biofeed-
back signal. End-expiratory plateau values of eNO are re-
corded and selected for averaging to obtain eNO. The initial
part of the expiration may show a peak in eNO, corresponding
to NO accumulated in the dead space volume (7). Although
this peak has been shown to correlate with plateau values, it
has not gained acceptance, perhaps because its magnitude de-
pends on breath holding and flow pattern. The relationship
between peak eNO and area under the curve (AUC) of the
whole tracing is not surprising as the peak often provides a
large contribution to the AUC. A final possibility for on-line
recording is that air can be sampled during quiet tidal breath-
ing through a mouthpiece with or without resistor. NO in ex-
haled air, recorded by a fast analyzer, can then be calculated
as an average signal over several breaths.
Exhaled NO depends on ambient NO concentration; in
particular, the initial (dead space) volume may be contami-
nated by high ambient NO values. Formal studies evaluating
the influence of ambient NO on eNO have been performed
both in adults and children, and reach remarkably different
conclusions (11–13). This may well be because of differences
in methodologies. Devices that deliver NO-free air to the in-
spiration circuit have been developed, and are incorporated in
some of the commercial analyzer systems. The effect of ele-
vated ambient NO on end-expiratory NO values is probably
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minor. High ambient levels will prolong the exhalation time
necessary to reach a plateau.
There are limited data on eNO measured on-line in babies
(14, 15). Air sampling in this age group has been tried by using
forced expiration and by collecting mixed expired air during
quiet breathing. Published work suggests that contamination
from the nose may not be as important as in older subjects
(16). A single research group has tried sampling of nasal air,
with and without occlusion, in premature and term infants.
These measurements show an initial expiratory peak, depend-
ing on the occlusion time, suggesting some nasal NO produc-
tion (17, 18).
 
Off-line sampling.
 
 Exhaled air can also be collected in an
NO-inert storage bag (made of, e.g., Mylar Tedlar, or polyeth-
ylene; party balloons are excellent) and analyzed later. This
method is attractive when subjects are studied in the home or
school environment, where samples can be obtained without
direct presence of an analyzer. NO has been shown to remain
stable in suitable bags for several hours, with or without a fa-
cility to absorb water vapor (19). Bags can be transported to
the analyzer and measured at a convenient time later in the
day. The flow during balloon blowing can be standardized, by
including a manometer and fixed resistor in the blowing channel
(19), or can be uncontrolled (20). Sufficient resistance should
be present to assure closing of the soft palate, which avoids nasal
contamination during filling of the balloon (4, 21). Essentially,
air can be collected during a single deep expiration, or during
tidal breathing through a nonrebreathing valve, collecting the
expired air in a balloon. Both methods have been shown to
produce broadly similar results, and with suitable flows and
resistance, correspond to those of on-line sampling (20, 21).
Off-line sampling in babies is possible but published data
are scarce. In this age group, contamination may be less im-
portant than in older children, and collection of mixed nasal
and oral exhaled air seems a promising diagnostic tool (22, 23).
 
Clinical applications of eNO.
 
 Several conditions have been
shown to produce elevated eNO in adults and children.
Among these are asthma (24–26), where NO is enhanced dur-
ing exacerbations (27, 28) and by natural allergen exposure in
adults (29) and children (16), viral infections of the upper air-
way (30, 31), and atopy. In asthmatic children, eNO correlates
with the eosinophil percentage in induced sputum (32, 33)
and, in a single study, with eosinophil cationic protein (ECP)
in induced sputum and with urinary excretion of eosinophil
protein X (33). Hence, eNO appears to reflect eosinophilic
airway inflammation.
Slightly increased eNO levels were found in lung transplant
recipients who developed rejection (34, 35) and in adults with
fibrosing alveolitis (36). Other diseases have shown normal,
varying or low eNO values: cystic fibrosis (37–39), ciliary dys-
kinesia (8, 23, 40), bronchiectasis, chronic obstructive pulmo-
nary disease (41, 42) and smoking (43, 44), and adult respira-
tory distress syndrome (45). NO appeared to differentiate
chronic cough due to asthma or nonasthmatic causes (46).
Hence, eNO should be studied for its differentiating capacity
as a new diagnostic tool. Data indicate that eNO may also be
useful in differential diagnosis of lung disease in infants (23).
The possible use of eNO to guide antiinflammatory treat-
ment should be further explored. Steroids reduce eNO in
adults (47, 48) and children (49) with asthma. Data from
adults indicate that inhaled steroids will reduce eNO to normal
levels even before an effect on symptoms is apparent (50).
This suggests that eNO shows a fast response. eNO may be
used as a measure of compliance with steroid treatment, or
perhaps as a predictor of relapse after discontinuation of anti-
inflammatory treatment.
 
Carbon monoxide.
 
 The possible use of exhaled CO as a
marker of oxidative stress in the airways, including asthmatic
airway inflammation, has been suggested (51). Horváth and
coworkers (52) showed that individuals with asthma have, on
average, slightly higher CO concentrations in their exhaled air
than healthy subjects, especially when no steroids are taken.
In another study, marginally increased CO values were also
found in exhaled air of adult patients with bronchiectasis (53).
The study showed that CO excretion was a consequence of in-
creased expression of heme oxygenase in macrophages. No
studies have been published on exhaled CO in children. One
preliminary report showed no difference in exhaled CO in pa-
tients with asthma and healthy controls (54). These data sug-
gest that it is unlikely that exhaled CO will be a useful marker.
 
Other markers.
 
 To date, no other markers in the gaseous
phase have been studied in children. In adults, a number of
studies have evaluated exhale volatile alkanes as markers of
inflammation, by means of gas chromatography (55). In adults
with asthma or obstructive sleep apnea, elevated levels of pen-
tane, a marker of free radical activity, were found in nasal and
oral exhaled air (56, 57).
 
Exhaled Markers in Breath Condensate
 
Collection of exhaled air condensate.
 
 Condensate can be ob-
tained by passing exhaled air through a cold tube, the material
of which should be appropriate for the retrieval of the sub-
stances under examination (glass in the case of hydrogen per-
oxide, Teflon for cysteinyl LTs). Glass tubes or vessels, cooled
to 0
 
8
 
 C with iced water, have been used (58–60), and conden-
sate can also be obtained by blowing air through a storage ves-
sel in ice or liquid nitrogen, capturing any water vapor in the
exhalate as ice on the walls of the vessel (61). Frozen conden-
sate can be stored until analysis, and remains stable for several
months (at least shown for H
 
2
 
O
 
2
 
 [62]). The importance of
collecting and storing the condensate in the dark to avoid
breakdown of substances of interest has not been evaluated.
Peroxide concentrations can be assessed by fluorimetry of
the reaction product of peroxide, horseradish peroxidase, and
parahydroxyphenylacetic acid, with concentrations deter-
mined from interpolation of a standard curve of H
 
2
 
O
 
2
 
 as de-
scribed in detail elsewhere (59). A limitation is that the
amount of condensate necessary for duplicate determination
requires about 10 min of tidal breathing by a school-aged
child, and is not feasible for most children younger than about
3 yr. Also, contamination of condensate by saliva, a rich
source of peroxide, mediators, cytokines, and other proteins,
should be avoided. The absence of saliva contamination can
be checked by determining amylase in the condensates; amy-
lase is abundant in saliva, whereas only traces are present in
lower airway secretions. Finally, condensate has been col-
lected from mechanically ventilated patients by draining the
(cooled) expiratory ventilator tubing (63).
 
Hydrogen peroxide.
 
 Hydrogen peroxide is produced by in-
flammatory cells and macrophages, and can be detected in ex-
haled air condensate. Increased levels have been found in
adult cigarette smokers (64), adults with asthma (65), and in
children with unstable (58) and stable (59) asthma. In addi-
tion, increased levels of H
 
2
 
O
 
2
 
 have been demonstrated in indi-
viduals with common colds and in patients with cystic fibrosis
(62). In cystic fibrosis, exhaled peroxide falls with antibiotic
treatment (66). In adult patients with asthma, the H
 
2
 
O
 
2
 
 con-
centration in breath condensate correlates with sputum eosin-
ophilia, but not with hyperresponsiveness (60). Exhaled H
 
2
 
O
 
2
 
responds to antibiotic treatment in cystic fibrosis, and is therefore
of potential use in monitoring cystic fibrosis treatment. Reference
ranges have been published for school-aged children (62).
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Leukotrienes.
 
 There have been few studies on levels of LTs
in exhaled air condensate, mainly focusing on the chemotactic
LTB
 
4
 
 and the cysteinyl LTs (LTC
 
4
 
, LTD
 
4
 
, and LTE
 
4
 
). One
group, using condensate collected via Teflon tubing to avoid
retention of LT by adsorption to glass, has found increased
levels of LT in asthma (67). A weak point in these studies is
that salivary contamination was not ruled out, and may ac-
count for the findings. Methodological differences in conden-
sate collection (especially saliva contamination) may be re-
sponsible for discrepancies between studies. There are no
published data for children.
 
Other substances in condensate.
 
 Oxidation metabolites of
NO may be elevated in condensate, even if NO is not elevated
in the gas phase, perhaps because of local metabolism in ab-
normal airways. This has been shown in patients with cystic fi-
brosis (68).
The presence of thiobarbituric acid-reactive products
(TBARs) in condensate of exhaled air has been demonstrated
in adults with asthma (65). TBARs are oxidation products of
lipids that are thought to result from oxidant damage of the
airway tissues. No data are available on TBARs in children.
In ventilated adults with respiratory distress syndrome, ele-
vated levels of isoprostanes have been described in breath
condensate (63). Isoprostanes are prostanoids that may reflect
oxidant stress in the airways; they have not been studied in pe-
diatric airway disease.
Another approach to assess exhaled substances is to per-
form two-dimensional polyacrylamide gel electrophoresis
(PAGE) of condensates, and stain the resulting image for pro-
teins. Characterization is possible on the basis of their place in
the electropherogram, or by molecular techniques. Few data
have been published (61), and as patients in these studies were
encouraged to exhale forcefully, it seems likely that contami-
nation with saliva may explain at least part of the results. Us-
ing PAGE and sensitive enzyme-linked immunosorbent assay
(ELISA) techniques, we have been unable to detect signifi-
cant amounts of protein in breath condensate that was not
contaminated by saliva (our unpublished results, 1999).
 
WHAT DO WE NEED TO KNOW/HOW CAN
WE ACHIEVE THIS?
 
NO Measurements: On-line Sampling
 
Can the procedure be standardized around desired flow with
respect to, for example, equipment, target flow (dependent on
lung size?), duration of plateau, and allowed variation around
desired flow? Can on-line sampling be facilitated with special
biofeedback software, and how important is ambient NO with
different sampling techniques? We need to achieve active flow
regulation, avoiding inaccurate blowing of target flow, and
age-dependent reference values are needed with standardized
methodology. eNO should also be validated against invasive
(preferably biopsy) studies of airway inflammation in different
patient groups and healthy children of different ages.
 
NO Measurements: Off-line Sampling
 
How important is flow standardization with off-line sampling
and how can it be achieved? Is it advantageous to discard dead
space volume from balloons? What ambient NO levels are ac-
ceptable and how can the effects of higher values be elimi-
nated? Off-line methods need to be evaluated in infants and
toddlers with respect to feasibility, methods of eliminating na-
sal NO, normal values, and applications. In older children,
normal values are needed with standardized methodology.
 
Clinical Applications of eNO
 
The sensitivity and specificity of eNO need to be evaluated in
differentiating airway diseases, using standardized methodolo-
gies in different age groups. The time course of changes in
eNO with changes in treatment or disease activity should also
be investigated. Can eNO be used as a marker for various pa-
thologies, including nonrespiratory disease, and what is the
predictive value of eNO with respect to treatment success or
relapse after reduction/discontinuation of treatment? The
added value of measuring eNO, above other common markers
of disease activity (symptoms, lung function, hyperresponsive-
ness, etc.), should also be determined.
 
Carbon Monoxide
 
Is exhaled CO elevated in inflammatory airway disease in chil-
dren? We need to investigate methodologies, normal values,
and reproducibility.
 
Hydrogen Peroxide
 
Exhaled peroxide should be validated against the gold stan-
dard of airway inflammation (biopsies). What is the role of ex-
haled peroxide in the diagnosis and management of childhood
asthma, cystic fibrosis, and other inflammatory conditions of
the airways? Can the methodology be adapted for infants and
toddlers, and is exhaled peroxide (unlike eNO) sensitive to
changes in the dose of antiinflammatory medication? Further-
more, can exhaled peroxide be used to predict the response to
or the risk of relapse after reducing/stopping treatment?
 
Other Markers in Condensate
 
Are these candidate markers detectable in exhaled air con-
densate of children, and are they elevated in inflammatory air-
way disease? Information is needed on appropriate methodol-
ogy, normal values, and reproducibility.
 
CONCLUSIONS
 
Exhaled air is a newly recognized vehicle of several interesting
markers of airway inflammation. Presently, a number of ap-
propriate molecules have been identified, and now we need
data on their validity, reproducibility, specificity and sensitiv-
ity, and normal ranges and on their possible use in research,
diagnosis, and treatment of inflammatory airway disease in
various age groups. Before such data are available, it makes
little sense to promote application in daily practice.
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